Baker McKenzie advises Novonesis on dsm-firmenich share sale
Baker McKenzie advised Danish biotechnology company Novonesis on its acquisition of dsm-firmenich’s share in the Feed Enzyme Alliance.
The context
Novonesis is a global biotechnology company with headquarters in Bagsværd, just outside Copenaghen, formed through a merger of Chr. Hansen and Novozymes.
In connection with the deal, the Danish company and dsm-firmenich met at EUR 1.5 billion, under the agreement to dissolve Feed Enzyme Alliance. As a result of the transaction, the buyer takes over the Alliance’ sales and distribution activities, thus bolstering Novonesis’ operations across the animal biosolutions value chain.
The team
Led by global head of M&A, Jannan Crozier, London M&A partner, Robert Gray and Novonesis relationship partner Gavin Bushell, the Baker Mckenzie team representing Novonesis worked across the cities of London, Amsterdam, Brussels, and Zurich. Partner Matthias Trautmann (pictured) handled the operation from the Zurich office, alongside senior associate Cathrin Marxer.
